In-Silico Drug Discovery Market Size, Top Share, Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global In-Silico Drug Discovery Market Size Analysis

Global In-Silico Drug Discovery Market Introduction
Based on Product
1. Introduction
  1. Based on Product By Value
2. Software
  1. By Value
3. Software-as-a-Service
  1. By Value
4. Consultancy-as-a-Service
  1. By Value
Based on Workflow
1. Introduction
  1. Based on Workflow By Value
2. Discovery
  1. By Value
3. Pre-Clinical Tests
  1. By Value
4. Clinical Tests
  1. By Value
Based on Technology
1. Introduction
  1. Based on Technology By Value
2. Artificial Intelligence
  1. By Value
Based on Target Therapeutic Area
1. Introduction
  1. Based on Target Therapeutic Area By Value
2. HIV
  1. By Value
3. Infectious diseases
  1. By Value
4. Metabolic disorders
  1. By Value
5. Mental disorders
  1. By Value
6. Musculoskeletal disorders
  1. By Value
7. Neurological disorders
  1. By Value
8. Oncological disorders
  1. By Value
9. Respiratory disorders
  1. By Value
10. Skin disorders
  1. By Value
11. Urogenital disorders
  1. By Value
12. Autoimmune disorders
  1. By Value
13. Blood disorders
  1. By Value
14. Cardiovascular disorders
  1. By Value
15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
  1. By Value
Based on End-User
1. Introduction
  1. Based on End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutes
  1. By Value

North America Market Analysis

Introduction
Based on Product
1. Introduction
  1. Based on Product By Value
2. Software
  1. By Value
3. Software-as-a-Service
  1. By Value
4. Consultancy-as-a-Service
  1. By Value
Based on Workflow
1. Introduction
  1. Based on Workflow By Value
2. Discovery
  1. By Value
3. Pre-Clinical Tests
  1. By Value
4. Clinical Tests
  1. By Value
Based on Technology
1. Introduction
  1. Based on Technology By Value
2. Artificial Intelligence
  1. By Value
Based on Target Therapeutic Area
1. Introduction
  1. Based on Target Therapeutic Area By Value
2. HIV
  1. By Value
3. Infectious diseases
  1. By Value
4. Metabolic disorders
  1. By Value
5. Mental disorders
  1. By Value
6. Musculoskeletal disorders
  1. By Value
7. Neurological disorders
  1. By Value
8. Oncological disorders
  1. By Value
9. Respiratory disorders
  1. By Value
10. Skin disorders
  1. By Value
11. Urogenital disorders
  1. By Value
12. Autoimmune disorders
  1. By Value
13. Blood disorders
  1. By Value
14. Cardiovascular disorders
  1. By Value
15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
  1. By Value
Based on End-User
1. Introduction
  1. Based on End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutes
  1. By Value
U.S.
1. Based on Product
  1. Introduction
    1. Based on Product By Value
  2. Software
    1. By Value
  3. Software-as-a-Service
    1. By Value
  4. Consultancy-as-a-Service
    1. By Value
2. Based on Workflow
  1. Introduction
    1. Based on Workflow By Value
  2. Discovery
    1. By Value
  3. Pre-Clinical Tests
    1. By Value
  4. Clinical Tests
    1. By Value
3. Based on Technology
  1. Introduction
    1. Based on Technology By Value
  2. Artificial Intelligence
    1. By Value
4. Based on Target Therapeutic Area
  1. Introduction
    1. Based on Target Therapeutic Area By Value
  2. HIV
    1. By Value
  3. Infectious diseases
    1. By Value
  4. Metabolic disorders
    1. By Value
  5. Mental disorders
    1. By Value
  6. Musculoskeletal disorders
    1. By Value
  7. Neurological disorders
    1. By Value
  8. Oncological disorders
    1. By Value
  9. Respiratory disorders
    1. By Value
  10. Skin disorders
    1. By Value
  11. Urogenital disorders
    1. By Value
  12. Autoimmune disorders
    1. By Value
  13. Blood disorders
    1. By Value
  14. Cardiovascular disorders
    1. By Value
  15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
    1. By Value
5. Based on End-User
  1. Introduction
    1. Based on End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Canada

Europe Market Analysis

Introduction
Based on Product
1. Introduction
  1. Based on Product By Value
2. Software
  1. By Value
3. Software-as-a-Service
  1. By Value
4. Consultancy-as-a-Service
  1. By Value
Based on Workflow
1. Introduction
  1. Based on Workflow By Value
2. Discovery
  1. By Value
3. Pre-Clinical Tests
  1. By Value
4. Clinical Tests
  1. By Value
Based on Technology
1. Introduction
  1. Based on Technology By Value
2. Artificial Intelligence
  1. By Value
Based on Target Therapeutic Area
1. Introduction
  1. Based on Target Therapeutic Area By Value
2. HIV
  1. By Value
3. Infectious diseases
  1. By Value
4. Metabolic disorders
  1. By Value
5. Mental disorders
  1. By Value
6. Musculoskeletal disorders
  1. By Value
7. Neurological disorders
  1. By Value
8. Oncological disorders
  1. By Value
9. Respiratory disorders
  1. By Value
10. Skin disorders
  1. By Value
11. Urogenital disorders
  1. By Value
12. Autoimmune disorders
  1. By Value
13. Blood disorders
  1. By Value
14. Cardiovascular disorders
  1. By Value
15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
  1. By Value
Based on End-User
1. Introduction
  1. Based on End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutes
  1. By Value
U.K.
1. Based on Product
  1. Introduction
    1. Based on Product By Value
  2. Software
    1. By Value
  3. Software-as-a-Service
    1. By Value
  4. Consultancy-as-a-Service
    1. By Value
2. Based on Workflow
  1. Introduction
    1. Based on Workflow By Value
  2. Discovery
    1. By Value
  3. Pre-Clinical Tests
    1. By Value
  4. Clinical Tests
    1. By Value
3. Based on Technology
  1. Introduction
    1. Based on Technology By Value
  2. Artificial Intelligence
    1. By Value
4. Based on Target Therapeutic Area
  1. Introduction
    1. Based on Target Therapeutic Area By Value
  2. HIV
    1. By Value
  3. Infectious diseases
    1. By Value
  4. Metabolic disorders
    1. By Value
  5. Mental disorders
    1. By Value
  6. Musculoskeletal disorders
    1. By Value
  7. Neurological disorders
    1. By Value
  8. Oncological disorders
    1. By Value
  9. Respiratory disorders
    1. By Value
  10. Skin disorders
    1. By Value
  11. Urogenital disorders
    1. By Value
  12. Autoimmune disorders
    1. By Value
  13. Blood disorders
    1. By Value
  14. Cardiovascular disorders
    1. By Value
  15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
    1. By Value
5. Based on End-User
  1. Introduction
    1. Based on End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
Based on Product
1. Introduction
  1. Based on Product By Value
2. Software
  1. By Value
3. Software-as-a-Service
  1. By Value
4. Consultancy-as-a-Service
  1. By Value
Based on Workflow
1. Introduction
  1. Based on Workflow By Value
2. Discovery
  1. By Value
3. Pre-Clinical Tests
  1. By Value
4. Clinical Tests
  1. By Value
Based on Technology
1. Introduction
  1. Based on Technology By Value
2. Artificial Intelligence
  1. By Value
Based on Target Therapeutic Area
1. Introduction
  1. Based on Target Therapeutic Area By Value
2. HIV
  1. By Value
3. Infectious diseases
  1. By Value
4. Metabolic disorders
  1. By Value
5. Mental disorders
  1. By Value
6. Musculoskeletal disorders
  1. By Value
7. Neurological disorders
  1. By Value
8. Oncological disorders
  1. By Value
9. Respiratory disorders
  1. By Value
10. Skin disorders
  1. By Value
11. Urogenital disorders
  1. By Value
12. Autoimmune disorders
  1. By Value
13. Blood disorders
  1. By Value
14. Cardiovascular disorders
  1. By Value
15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
  1. By Value
Based on End-User
1. Introduction
  1. Based on End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutes
  1. By Value
China
1. Based on Product
  1. Introduction
    1. Based on Product By Value
  2. Software
    1. By Value
  3. Software-as-a-Service
    1. By Value
  4. Consultancy-as-a-Service
    1. By Value
2. Based on Workflow
  1. Introduction
    1. Based on Workflow By Value
  2. Discovery
    1. By Value
  3. Pre-Clinical Tests
    1. By Value
  4. Clinical Tests
    1. By Value
3. Based on Technology
  1. Introduction
    1. Based on Technology By Value
  2. Artificial Intelligence
    1. By Value
4. Based on Target Therapeutic Area
  1. Introduction
    1. Based on Target Therapeutic Area By Value
  2. HIV
    1. By Value
  3. Infectious diseases
    1. By Value
  4. Metabolic disorders
    1. By Value
  5. Mental disorders
    1. By Value
  6. Musculoskeletal disorders
    1. By Value
  7. Neurological disorders
    1. By Value
  8. Oncological disorders
    1. By Value
  9. Respiratory disorders
    1. By Value
  10. Skin disorders
    1. By Value
  11. Urogenital disorders
    1. By Value
  12. Autoimmune disorders
    1. By Value
  13. Blood disorders
    1. By Value
  14. Cardiovascular disorders
    1. By Value
  15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
    1. By Value
5. Based on End-User
  1. Introduction
    1. Based on End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
Based on Product
1. Introduction
  1. Based on Product By Value
2. Software
  1. By Value
3. Software-as-a-Service
  1. By Value
4. Consultancy-as-a-Service
  1. By Value
Based on Workflow
1. Introduction
  1. Based on Workflow By Value
2. Discovery
  1. By Value
3. Pre-Clinical Tests
  1. By Value
4. Clinical Tests
  1. By Value
Based on Technology
1. Introduction
  1. Based on Technology By Value
2. Artificial Intelligence
  1. By Value
Based on Target Therapeutic Area
1. Introduction
  1. Based on Target Therapeutic Area By Value
2. HIV
  1. By Value
3. Infectious diseases
  1. By Value
4. Metabolic disorders
  1. By Value
5. Mental disorders
  1. By Value
6. Musculoskeletal disorders
  1. By Value
7. Neurological disorders
  1. By Value
8. Oncological disorders
  1. By Value
9. Respiratory disorders
  1. By Value
10. Skin disorders
  1. By Value
11. Urogenital disorders
  1. By Value
12. Autoimmune disorders
  1. By Value
13. Blood disorders
  1. By Value
14. Cardiovascular disorders
  1. By Value
15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
  1. By Value
Based on End-User
1. Introduction
  1. Based on End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutes
  1. By Value
UAE
1. Based on Product
  1. Introduction
    1. Based on Product By Value
  2. Software
    1. By Value
  3. Software-as-a-Service
    1. By Value
  4. Consultancy-as-a-Service
    1. By Value
2. Based on Workflow
  1. Introduction
    1. Based on Workflow By Value
  2. Discovery
    1. By Value
  3. Pre-Clinical Tests
    1. By Value
  4. Clinical Tests
    1. By Value
3. Based on Technology
  1. Introduction
    1. Based on Technology By Value
  2. Artificial Intelligence
    1. By Value
4. Based on Target Therapeutic Area
  1. Introduction
    1. Based on Target Therapeutic Area By Value
  2. HIV
    1. By Value
  3. Infectious diseases
    1. By Value
  4. Metabolic disorders
    1. By Value
  5. Mental disorders
    1. By Value
  6. Musculoskeletal disorders
    1. By Value
  7. Neurological disorders
    1. By Value
  8. Oncological disorders
    1. By Value
  9. Respiratory disorders
    1. By Value
  10. Skin disorders
    1. By Value
  11. Urogenital disorders
    1. By Value
  12. Autoimmune disorders
    1. By Value
  13. Blood disorders
    1. By Value
  14. Cardiovascular disorders
    1. By Value
  15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
    1. By Value
5. Based on End-User
  1. Introduction
    1. Based on End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
Based on Product
1. Introduction
  1. Based on Product By Value
2. Software
  1. By Value
3. Software-as-a-Service
  1. By Value
4. Consultancy-as-a-Service
  1. By Value
Based on Workflow
1. Introduction
  1. Based on Workflow By Value
2. Discovery
  1. By Value
3. Pre-Clinical Tests
  1. By Value
4. Clinical Tests
  1. By Value
Based on Technology
1. Introduction
  1. Based on Technology By Value
2. Artificial Intelligence
  1. By Value
Based on Target Therapeutic Area
1. Introduction
  1. Based on Target Therapeutic Area By Value
2. HIV
  1. By Value
3. Infectious diseases
  1. By Value
4. Metabolic disorders
  1. By Value
5. Mental disorders
  1. By Value
6. Musculoskeletal disorders
  1. By Value
7. Neurological disorders
  1. By Value
8. Oncological disorders
  1. By Value
9. Respiratory disorders
  1. By Value
10. Skin disorders
  1. By Value
11. Urogenital disorders
  1. By Value
12. Autoimmune disorders
  1. By Value
13. Blood disorders
  1. By Value
14. Cardiovascular disorders
  1. By Value
15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
  1. By Value
Based on End-User
1. Introduction
  1. Based on End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutes
  1. By Value
Brazil
1. Based on Product
  1. Introduction
    1. Based on Product By Value
  2. Software
    1. By Value
  3. Software-as-a-Service
    1. By Value
  4. Consultancy-as-a-Service
    1. By Value
2. Based on Workflow
  1. Introduction
    1. Based on Workflow By Value
  2. Discovery
    1. By Value
  3. Pre-Clinical Tests
    1. By Value
  4. Clinical Tests
    1. By Value
3. Based on Technology
  1. Introduction
    1. Based on Technology By Value
  2. Artificial Intelligence
    1. By Value
4. Based on Target Therapeutic Area
  1. Introduction
    1. Based on Target Therapeutic Area By Value
  2. HIV
    1. By Value
  3. Infectious diseases
    1. By Value
  4. Metabolic disorders
    1. By Value
  5. Mental disorders
    1. By Value
  6. Musculoskeletal disorders
    1. By Value
  7. Neurological disorders
    1. By Value
  8. Oncological disorders
    1. By Value
  9. Respiratory disorders
    1. By Value
  10. Skin disorders
    1. By Value
  11. Urogenital disorders
    1. By Value
  12. Autoimmune disorders
    1. By Value
  13. Blood disorders
    1. By Value
  14. Cardiovascular disorders
    1. By Value
  15. Gastrointestinal and digestive disorders, hormonal disorders, and others.
    1. By Value
5. Based on End-User
  1. Introduction
    1. Based on End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutes
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

In-Silico Drug Discovery Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Albany Molecular Research Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Certara
Charles River Laboratories
Chemical Computing Group ULC
GenScript
LakePharma Inc.
Sygnature Discovery
Abzena Ltd.
BioNTech SE
Creative Biostructure

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment